BioCentury | May 18, 2015
Financial News

Diagnostic BioSystems completes venture financing

Diagnostic BioSystems Inc. , Pleasanton, Calif. Business: Diagnostic, Supply/Service, Antibodies Date completed: 2015-05-11 Type: Venture financing Raised: Not disclosed Investor: BroadOak Capital Partners Note: The amount raised is not disclosed. WIR Staff Diagnostic...
BioCentury | Dec 6, 2010
Company News

Biosystems International, Pharnext, Bordeaux Hospital, INSERM, OSEO, University Bordeaux Segalen neurology news

OSEO is eligible for royalties during the first three years of the deal if net sales are higher than a pre-defined, undisclosed figure. Biosystems International S.A.S. , Evry, France Pharnext S.A.S. , Paris, France Bordeaux Hospital , Bordeaux,...
BioCentury | Feb 27, 2006
Company News

BioSystems International, AstraZeneca deal

The companies partnered to identify biomarkers for osteoporosis. The deal combines BioSystems' biomarker validation technologies with clinical samples from AZN. The pharma company will provide funding and will have exclusive rights to any new targets...
Items per page:
1 - 3 of 3
BioCentury | May 18, 2015
Financial News

Diagnostic BioSystems completes venture financing

Diagnostic BioSystems Inc. , Pleasanton, Calif. Business: Diagnostic, Supply/Service, Antibodies Date completed: 2015-05-11 Type: Venture financing Raised: Not disclosed Investor: BroadOak Capital Partners Note: The amount raised is not disclosed. WIR Staff Diagnostic...
BioCentury | Dec 6, 2010
Company News

Biosystems International, Pharnext, Bordeaux Hospital, INSERM, OSEO, University Bordeaux Segalen neurology news

OSEO is eligible for royalties during the first three years of the deal if net sales are higher than a pre-defined, undisclosed figure. Biosystems International S.A.S. , Evry, France Pharnext S.A.S. , Paris, France Bordeaux Hospital , Bordeaux,...
BioCentury | Feb 27, 2006
Company News

BioSystems International, AstraZeneca deal

The companies partnered to identify biomarkers for osteoporosis. The deal combines BioSystems' biomarker validation technologies with clinical samples from AZN. The pharma company will provide funding and will have exclusive rights to any new targets...
Items per page:
1 - 3 of 3